Public reporting burden for this collection of information is estimated to average 1 hour per response. including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed and completing and reviewing this collection of information Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense Washington Headquarters Services Directorate for Information Abstract HAl-W was initially identified as cognate inhibitor of matriptase, a membrane-bound serine protease. Paradoxically HAM-1 is also required for matriptase activation, a process that requires sphingosine 1-phosphate (S1P)-mediated translocation of the protease to cell-cell junctions in human mammary epithelial cells. In the current report, we further explored how HAl-1 regulates this protease. First we observed that following S1 P treatment HAl-1 was co-translocated with matriptase to cellcell junctions and that the cellular ratio of HAl-1 to matriptase was maintained during this process. However, when this ratio was changed by cell treatment with HAl-i siRNA or anti-HAl-1 mAb M19, spontaneous activation of matriptase occurred in the absence of SIP-induced translocation; SIP-induced matriptase activation was also enhanced. These results support a role for HAl-1 in protection of cell from uncontrolled matriptase activation. We next expressed matriptase, either alone or with HAl-1 in breast cancer cells that do not endogenously express either protein. A defect in matriptase trafficking to the cell surface occurred if wild type matriptase was expressed in the absence of HAl-i; this defect appeared to result from matriptase toxicity to cells. Coexpression with matriptase of wild type HAl-i, but not HAl-1 mutants altered in its Kunitz domain 1, corrected the trafficking defect. In contrast, catalytically defective matriptase mutants were normal in their trafficking in the absence of HAl-1. These results are also consistent with a role for HAl-1 to prevent inappropriate matriptase proteolytic activity during its protein synthesis and trafficking. Taken together, these results support multiple roles for HAl-1 to regulate matriptase, including its proper expression, intracellular trafficking, activation, and inhibition.
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Georgetown University Washington, DC 20007 Introduction:
The death of women with breast carcinoma mainly results from metastasis. Metastatic breast cancer cells must escape from a primary tumor and migrate through anatomical barriers in order to gain access to the blood or lymphatic system and establish at a new site in the body. Cellular motility and degradation of extracellular matrix (ECM) are two of the major events in breast cancer metastasis and can be promoted by stromal-derived, ECM-degrading protease systems, such as the urokinase type plasminogen activator (uPA) system and by motility factors, such as hepatocyte growth factor (HGF)/scatter factor (SF). In order to understand how breast cancer cells regulate both stromal-derived, ECM degradation and cellular motility for metastasis, we have discovered and characterized in human breast cancer a new epithelial-derived, type 2 integral membrane, serine protease, matriptase, and its cognate inhibitor, a Kunitz-type serine protease (KSPI), a type I integral membrane protein which was initially identified as an inhibitor of hepatocyte growth factor activator and named as HAI-I (1-3). Both matriptase and HAI-I have been implicated in the regulation of ECM-degradation of cellular motility (4) . In the current research plan, we proposed to study the anti-tumor and anti-protease activity of this membrane-bound Kunitz inhibitor.
Body:
During the August 04-July 05 period we had addressed Aim 3 of the original proposal: Year 4: In the final year, we will continue the characterization of both KSPI-complexes.
In the previous year, we have finished the role of KSPI (now termed HAI-1) in matriptase activation and inhibition. The transfection of HAI-1 in breast cancer cells have been completed and reported in the annual report of first year, and the new HAI-1 complex turns out to be HGF activator complexed with HAI-1. In the current report, we have further investigated how HAI-I regulated matriptase expression, trafficking and activation in cell biology aspects. These works have been published in American Journal Physiology-Cell Physiology (289:C462-70, 2005). We report here with these works. Please refer to the attached reprint for the Figures Proportional increase in HAI-1 and matriptase in individual cells and at cell-cell junctions--The close relationship between matriptase and its cognate inhibitor HAI-i was initially recognized in vitro by their concordant expression among cell lines (5), co-incidence on cell surfaces (6) and formation of stable complexes (1 ;3). We further showed that HAI-I is required for matriptase activation (7) , and that both proteins translocate to activation foci during the activation of the protease (8;9) . In 184 A1N4 immortal mammary epithelial cells, while expression levels of matriptase and HAI-I were not uniform among individual cells, proportional increases or decreases in matriptase and HAI-I were observed, comparing individual cells (Fig. 1 ). This relatively constant ratio between matriptase and HAI-I was even observed when both proteins were translocated to cell-cell junctions during S I P-induced activation of matriptase (Fig. 1) . Matriptase tended to accumulate more at the merging points of cell-cell contacts of three or four cells (focal points) (Fig. 1) . HAI-i shared this uneven distribution at cell-cell contacts, with higher levels of matriptase accompanied by higher levels of HAI-I (Fig. 1) . Because matriptase and HAI-i localization is restricted to common points of cell-cell contact, we sought to further explore the role of HAI-I in matriptase activation and intracellular trafficking.
Reduced expression of HAI-1 by HAI-1 siRNA caused spontaneous activation of matriptase-We reduced the levels of HAI-i by HAI-I siRNA to investigate its impact on matriptase activation. After 48 hr treatment with HAI-I siRNA, 184 AIN4 expressed much less HAI-1, as examined by immunoblot using anti-HAI-I mAb M19 (Fig. 2, M19 , comparing lane 4 with lane 2). The levels of total matriptase were not altered by HAI-I siRNA (Fig. 2, M32 , comparing lane 4 with lane 2). As expected from previous studies (10;11), activation of matriptase did not occur in these cells in the absence of an exogenous inducer, such as S IP (Fig. 2,  M69 lane 2) . However, reduced expression of HAI-I by siRNA in these cells caused spontaneous activation of matriptase (Fig. 2, M69 , comparing lane 4 with lane 2). As described previously (9), the activated matriptase was detected in 120-and 85-kDa complexes using mAb M69, which specifically recognizes the activated, two-4 chain matriptase. The ratio between 120-and 85-kDa complexes varied from experiment to experiment. As examined by immunofluorescence staining, activated matriptase was detected as a diffuse pattern, with some aggregation (Fig. 3 ). Because individual cells express different amount of HAI-I (Fig. 1) , the reduction of HAI-I expression by HAI-I siRNA, as seen in immunoblot (Fig. 2) , can not clearly be demonstrated by immunofluorescence staining (Fig. 3) . These data suggest that maintenance of a proper ratio between matriptase and HAI-I may be essential for prevention of spontaneous activation of matriptase in mammary epithelial cells.
Reduced HAI-1 expression significantly enhanced SIP-induced matriptase activation--When HAI-I siRNA-treated cells were induced by SIP for matriptase activation, a significant increase in activated matriptase was observed, compared to that in the control cells (Fig. 2, M69, comparing lane 3 to lane 1) . Immunofluorescent staining showed that, after S IP addition to cells, matriptase activation occurred primarily at the junction of multiple cells, and subsequently spread to cell to cell junctions between two adjacent cells. In the HAI-I siRNA-treated cells, more activated matriptase was detected in an elongated pattern along the cellcell junctions, compared to in the control cells (Fig. 4) . Because the expression levels of both matriptase and HAI-I varied substantially in individual 184 AIN4 cells, it was difficult to discern the reduced expression of HAI-I-1 by siRNA in some cells. For most SIP-treated cells, HAI-I was detected as a bright band along the cell-cell junctions, with diffuse areas of staining adjacent to the cell-cell junctions. HAI-1 siRNA caused the disappearance of the areas of diffuse staining in some cells, where the activated matriptase was detected in more elongated patterns. These data suggest that reduced HAI-I levels result in an increase in the activation of matriptase adjacent to cell-cell junctions, leading to higher total matriptase activation.
Pretreatment of 184 A1N4 cells with the anti-HAI-1 mAb M19 enhances SIP-induced matriptase activation -We further tested if the anti-HAI-1 mAb M19 could affect S IP-induced matriptase activation (Fig. 5) . Previously, we showed that pretreatment with anti-matriptase mAb M32, which recognizes the third LDL receptor domain of matriptase, inhibited SIP-induced matriptase activation in 184 AIN4 cells (8) . Thus, we incorporated mouse IgG and mAb M32 as the controls. After growth for two days, the cells were preincubated with 5 ýig/ml of mouse IgG, M32, or M19, respectively, for 1 hr. These pretreatments of cells with antibodies alone did not cause matriptase activation, as examined by immunoblot, but activated matriptase was observed by immunofluorescence staining in few scattered M 19-pretreated cells (data not shown). After stimulating these antibody-pretreated cells with SIP for 30 min, activated matriptase was detected in mouse IgG-pretreated cells, but not in M32-pretreated ones, as examined by immunoblot (Fig. 5A ) or by immunofluorescence staining (Fig. 5 B) . Much higher levels of activated matriptase were detected in mAb M19-pretreated cells, compared to those in mouse IgG-pretreated ones.
Immunofluorescence staining further revealed that the increase in matriptase activation by mAb M 19 resulted from two events: activation occurred in more cells and in a more elongated manner along cell-cell junctions (Fig. 5B) . Activated matriptase was detected in almost every single M19-pretreated cell, but only in approximately one half of mouse IgG-pretreated cells. Activated matriptase was detected predominately at the junction of multiple cells in the IgG-pretreated cells, whereas activated matriptase was visualized along nearly the entire cell borders of M l9-pretreated cells (Fig. 5B ).
HAI-1 is required for expression of matriptase--Given these complex and well-coordinated relationships between matriptase and HAI-I, it seems likely that HAI-1 may also play a role during matriptase biosynthesis and degradation. This notion was first supported when we attempted to exogenously express matriptase in BT549 breast cancer cells that do not endogenously express either matriptase or HAI-I. When BT549 cells were transiently transfected with wild-type matriptase alone, only a very low level of matriptase protein was detected by western blotting, using anti-matriptase mAb M32 upon long exposure of blots. However, transient transfection with a cDNA coding for HAI-I resulted in strong expression of exogenous HAI-I in these cells (Fig. 6 ). When the protease was co-transfected with the inhibitor, much higher levels of matriptase were seen. The poor expression of matriptase, when the protease was transfected alone, may result from its proteolytic activity, since exogenous expression of matriptase mutants altered in the catalytic triad 5 (S805A matriptase) or in the substrate binding pocket (D799A matriptase), were achieved in BT549 breast cancer cells, independently of the presence of HAI-I (Fig. 6 ). While high levels of matriptase expression were achieved for the matriptase mutant altered in its active site triad, coexpression of the inactive catalytic triad matriptase mutant with wild-type matriptase caused poor expression of both matriptase species (Fig. 6 ). These results suggest that unopposed matriptase proteolytic activity could be toxic for its expression, and that the presence of HAl-] corrects this toxic effect, leading to higher levels of matriptase expression.
Immunofluoresence staining using Texas red conjugated phalloidin (actin), together with the antimatriptase mAb M32 (Fig. 7A) , suggested that the poor expression was due to a defect in intracellular trafficking of the protease. Indeed, immunofluorescence using an antibody that recognizes GM 130, a Gogispecific marker, together with Alexa-Fluor®594-conjugated M32 matriptase-specific antibody (Fig. 7D) , revealed that matriptase accumulated in a cellular location consistent with the endoplasmic reticulum and Golgi apparatus. This defect in trafficking was corrected by cotransfection with HAI-1, as shown by immunofluorescence ( Fig. 7B and E) , and resulted in much improved expression of the protease, as shown by western blotting (Fig. 7A ). In addition, catalytically inactive mutants of matriptase altered in the catalytic triad (S805A matriptase) were able to traffic in the absence of HAI-I (Fig 7C) .
The proper trafficking and enhanced expression of the matriptase protein when co-transfected with HAI-I was not a phenomena limited to BT549 cells. Indeed, it was also seen when matriptase and HAI-I were transfected into MDA MB-231 and MDA MB-435 cancer cells (data not shown). These two cancer cell lines also neither express matriptase nor HAI-I (5).
The first Kunitz domain, but not the second, is required for HAI-1 to facilitate matriptase intracellular trafficking--Since the intracellular trafficking of matriptase depended upon HAI-I, we were able to test which domains in HAI-1 were essential for protease expression and trafficking. HAI-1 contains two Kunitz-type serine protease inhibitory domains, Kunitz domain I (at the amino terminus) and Kunitz domain II (at the carboxyl terminus), with an intervening LDL receptor class A domain (12) (Fig. 7) .
The Kunitz domain is an approximately 60 amino acid long serine protease inhibitory domain for which the bovine basic pancreatic trypsin inhibitor (BPTI) represents the prototypic structure (13) . The P1 residue of Kunitz-type inhibitory domains (the amino acid residue C-terminal to the second conserved cysteine residue) is recognized as the active center, responsible for the inhibitory specificity. For example, the corresponding amino acid residues in the Kunitz domains of HAI-I are Arg-260 in domain I and Lys-385 in domain II, and therefore these Kunitz domains are predicted to be specific for trypsin-like serine proteases such as matriptase (interacting with Asp-799 in the substrate binding pocket of matriptase). Mutation of Arg-260 will completely abolish the inhibitory activity of a Kunitz domain. Previously, molecular modeling strongly suggested that the first, but not the second, Kunitz domain of HAI-I is responsible for the inhibition of 14atriptase (14) . In addition to Arg-260, Arg-258 was also suggested to be crucial for the activity of Kunitz domain I. Therefore, we constructed point mutations at these three critical basic residues in Kunitz domains I and II (Arg-258, Arg-260, and Lys-385).
Mutation of critical arginine residues in the first Kunitz domain of HAI-I (R258L and R260L HAI-1) completely abolished the ability of HAI-I to facilitate the intracellular trafficking of matriptase (Fig. 8) . In cotransfection experiments with these HAI-I mutants, matriptase was poorly expressed, as determined by M32 western blotting, and did not traffic properly as determined by matriptase immunofluorescence (data not shown). Mutation of a critical basic residue in the second Kunitz domain of HAI-I (K385L HAI-I), however, did not affect the ability of HAI-I to facilitate matriptase trafficking, since matriptase expressed well ( Fig. 8 ) and underwent proper intracellular trafficking, as confirmed by matriptase immunofluorescence (data not shown). It should be noted that the R258L and R260L HAI-I mutants did not express well when transfected with matriptase, in contrast to the K385L HAI-I mutant (Fig. 8 ). However, this was due to the defect in intracellular trafficking created by unopposed matriptase activity, and not by poor transfection efficiency, as 6
determined by immunofluorescence staining (data not shown). These results suggest that matriptase proteolytic activity, which could result from spontaneous activation in the absence of HAI-I, generally interferes with the trafficking of transmembrane proteins when transfected in the absence of HAI-1.
Key research accomplishments:
" Conclusion:
In the current report, we further explored the role of HAI-I in the regulation of matriptase activation by reducing the expression levels of HAI-I or sequestering HAI-I using an anti-HAI-I monoclonal antibody. Interestingly, reduced HAI-I expression or availability caused spontaneous activation of matriptase and enhanced activation of matriptase by SIP. Furthermore, this spontaneous activation of matriptase was closely associated with a defect in the trafficking of the protease, and coexpression of HAI-I with matriptase corrected this defect. These results suggest that regulation of matriptase by HAI-I may occur at multiple levels, including protein biosynthesis, intracellular trafficking, prevention of uncontrolled spontaneous activation, regulated activation, and ectodomain shedding. xenograft model (7) . Furthermore, tor activator inhibitor-I (HAl-I) was initially identified as cognate inhibitor of matriptase, a membrane-bound serine protease. Paradoxmatriptase was shown to be essential for the epidermal cell ically, HAI-I is also required for matriptase activation, a process that maturation of profilaggrin, a large (>300 kDa) insoluble phos-0 requires sphingosine 1-phosphate (SIP)-mediated translocation of the phoprotein involved in terminal differentiation of keratinocytes . protease to cell-cell junctions in human mammary epithelial cells. In (19). The protease is also required for postnatal survival, U the present study, we further explored how HAl-I regulates this epidermal barrier function, hair follicle development, and thy-Cprotease. First, we observed that after SIP treatment HAI-I was mic homeostasis in mice (18). Matriptase belongs to the type 11 cotranslocated with matriptase to cell-cell junctions and that the transmembrane serine protease group. Members of the serine a cellular ratio of HAl-I to matriptase was maintained during this protease group are characterized by an amino-terminal trans-3 process. However, when this ratio was changed by cell treatment with membrane domain and multiple extracelhuar domains, in ad--o HAI-I small interfering RNA or anti-lIAI-I MAb M 19, spontaneous d activation of matriptase occurred in the absence of SIP-induced dition to the conserved extracellular serine protease catalytic ma translocation; SIP-induced matriptase activation was also enhanced.
n (8, 21, 27) . Both matriptase and --IAI-I are expressed These results support a role for HAl-I in protection of cell from t.n vivo by the epithelial components of most epitheliumuncontrolled matriptase activation. We next expressed matriptase, containing tissues (10, 23) and coincided on the surfaces of a0 either alone or with HAI-M in breast cancer cells that do not endog-cultured breast cancer cells (3) . Given the formation of tightly enously express either protein. A defect in matriptase trafficking to the bound complexes, coexpression by epithelial elements in vivo, 0 cell surface occurred if wild-type matriptase was expressed in the and coincidence on the cell surface, matriptase is a physiolog-3 0 absence of HAI-l; this defect appeared to result from matriptase ical target protease of HAI-I. toxicity to cells. Coexpression with matriptase of wild-type HAIM, Whereas HAI-I functions as the physiological inhibitor of , but not HAI-] mutants altered in its Kunitz domain 1, corrected the matriptase, this inhibitor is also involved in matriptase C trafficking defect. In contrast, catalytically defective matriptase mu-activation (24). Like most other serine proteases, activation "" tants were normal in their trafficking in the absence of HAI-I. These results are also consistent with a role for HAI-1 to prevent inappro-of matriptase requires cleavage at its canonical activation 90 priate matriptase proteolytic activity during its protein synthesis and motif to convert a single-chain zymogen to the two-chain trafficking. Taken together, these results support multiple roles for active enzyme (1). However, compared with most other oM HAI-] to regulate matriptase, including its proper expression, intra-serine proteases, in which activation is conducted by other cellular trafficking, activation, and inhibition, active proteases, matriptase activation depends on its own protease-activated receptor-2; hepatocyte growth factor; urokinase; active site triad (24). Therefore, matriplase tust transactivate itself, whereby interactions between at least two sphingosine Il-phosphate; Kunitz domain matriptase zymogens, and possibly other proteins, such as HAI-I, leads to the activation cleavage (24). This hypoth-1JEPATOCYTE GROWTH FACTOR (HGF) activator inhibitor 1 esis has been further supported by the fact that in immortal (HAI-I) is a type I integral membrane, Kunitz-type serine human mammary epithelial cells, mhatriptase and HAI-I are protease inhibitor (25). HAI-1 contains two Kunitz domains cotranslocated and accumulated at activation foci, either at and a low-density lipoprotein (LDL) receptor class A domain, cell-cell junctions or vesicle-like structures, during HAI-I was initially identified as an inhibitor of HGF activator matriptase activation induced, respectively, by blood-borne (25), a liver-derived, blood-borne serine protease, which is a sphingosine 1-phosphate (SIP) (1, 2, 9) or suramin, a potent activator of pro-HGF (20). Subsequently, HAL-I was sulfide-rich chemical (13) . The involvement of HAl-1 in purified from human milk as a complex with' matriptase, a matriptase activation therefore provides an efficient mechmultidomain, transmembrane serine protease of the SI trypsin-anism to inhibit active matriptase. Consequently, activated like family (11, 15, 16, 29, 30) . Matriptase has been implicated matriptase is almost exclusively detected in complexes ACTIVATION AND EXPRESSION OF MATRIPTASE C463 bound to HAI-I (13) . The dual functions of HAM-1 in both 4,6-diamidino-2-phenylindole. Golgi were visualized using the matriptase activation and inhibition suggest a critical role of GM130 monoclonal antibody (BD Biosciences, Palo Alto, CA), the inhibitor in the regulation of matriptase function, not followed by a secondary goat anti-moose FITC-conjugated antionly in suppression of undesired matriptase proteolysis, but body. For costaining of Golgi and matriptase, the GM 130 antibody also in the regulation of matriptase activation. In the present staining was followed by Alexa Fluor 594-conjugated M32 antiso body and a 100-fold excess of mouse IgG to prevent the crossstudy, we further explored the role of HA-I-in the regula-reaction of any GM130-bound goat anti-mouse FITC with the tion of matriptase activation by reducing the expression Alexa Fluor 594-conjugated M32 monoclonal antibody. After levels of HAI-I or sequestering HAI-I using an anti-HAl-I fluorescent staining, cover glasses were mounted with Prolong monoclonal antibody. Interestingly, reduced HAM-1 expres-Antifade (Molecular Probes), and the fluorescent images were sion or availability caused spontaneous activation of captured by the MetaVue software package (Molecular Devices) matriptase and enhanced activation of matriptase by SIP. on a Nikon Eclipse E600 digital fluorescence microscope. Furthermore, this spontaneous activation of matriptase was HAI-I small interfering RNA. Two independent small interfering closely associated with a defect in the trafficking of the (si)RNA target sites were selected in HAl-I using standard design protease, and coexpression of HAl-I with matriptase cor-criteria (5): HAt-IA, AACUGCAACUUGGCGCUAGU; and HAlrected this defect. These results suggest that regulation of lB, AGAUCUGCAAG AGUUUCGUU. Synthetic siRNA oligos irludiong o against these targets were purchased from Dharmacon in a duplexmatriptase by HA-I-may occur at multiple levels, ready 2'-angiotensin-converting enzyme-protected form and preprotein biosynthesis, intracellular trafficking, prevention of pared and stored according to the manufacturer's instructions. uncontrolled spontaneous activation, regulated activation, Cells plated on I8-mm-thick glass coverslips, for immunoltuoresand ectodomain shedding.
cence microscopy, or in tissue culture dishes, were transfected with the siRNA using oligofectamine and Opti-MEM medium (Invitro-0 MATERIALS AND METHODS gen, Carlsbad, CA), according to the manufacturer's instructions. Identical results were obtained with HAl-IA and HAl-I B (11), and ZChemicals and reagents. Formaldehyde solution was purchased control experiments that used siRNA directed against an irrelevant Cfrom EM Science (EM Industries, Bibbstown, NJ). Cytochalasin D, gene had no effect. suramin, and Ro-31-8220 were obtained from Biomol (Plymouth Constructs and transfections. The cDNA clones for the full-• Meeting, PA). Sphingosine I-phosphate (SIP) was obtained from length human matriptase coding sequence, or the full-length human 3 Avanti Polar Lipids (Alabaster, AL). SIP was prepared at a 10 jgl/ml HAI-1 coding sequence in the vector pcDNA3. l (Invitrogen), were . mixture in a solution containing BSA (I mg/ml), and was used to treat used in transient transfections. These constructs were also used to 0CD cells at 50 ng/ml. All other chemical reagents were obtained from make site-directed mutants of matriptase or HAI-L. For making .= Sigma-Aldrich (St. Louis, MO), unless otherwise specified.
site-directed mutations, the QuikChange Site Directed Mutagene-:r Cell culture conditions. Immortalized 184 A IN4 human mammary sis Kit (Stratagene, La Jolla, CA) was used with primers containing 0., epithelial cells were a gift from Dr. Martha Stampfer (Lawrence appropriate nucleotide changes, according to the manufacturer's 00 Berkeley National Laboratory, Berkeley, CA), and maintained as protocol. All deletion mutants were confirmed by DNA sequencdescribed in a previous study (1) . BT549 human breast cancer cells ing. For each mutant, at least two separately isolated expression o were cultured in Iscove's minimal essential media (Invitrogen, Rock-constructs were isolated and tested in transient transfections. Tran-3 0 ville, MD) supplemented with 5% fetal bovine serum in a humidified sient transfection of human matriptase or human HAI-I constructs =o chamber at 37°C and 5% CO 2 .
(wild type or mutant) was accomplished using Fugene 6 transfec-> Monoclonal antibodies and Western blot analysis. Human tion reagent (Roche Diagnostics, Indianapolis, IN), according to (a matriptase protein was detected using the M32 monoclonal anti-the manufacturer's protocol. When conducting cotransfections, the U) body, that recognizes the third LDL receptor domain of matriptase amount of DNA used with the transfection reagent was kept and can interact with both the latent (one chain) and activated (two constant for each individual transfection by including empty vector 00 chain) forms of the protease (9, 15). Activated matriptase was pcDNA3.1 DNA where appropriate. detected by the M69 monoclonal antibody (MAb), which recog-01 nizes an epitope present only in the activated, two-chain form of RESULTS the enzyme (1, 2). Human HAI-] was detected with the use of the HAl-I-specific monoclonal antibody M19 (15). The latent form Proportional increase in HAMI and matriptase in individual matriptase could be detected by MAb M32 at either 70 kDa (NH 2 cells and at cell-cell junctions. The close relationship beterminal processed form) or at 93 kDa (the full-length matriptase, seen mainly with forced expression of matriptase). The activated tween matriptase and its cognate inhibitor HAI-I was inimatriptase was detected by MAbs M69 or Ml 9 at 120 kDa (70-kDa tially recognized in vitro by their concordant expression active matriptase plus full-length HAl-I) or at 85 kDa (the full-among cell lines (22), coincidence on cell surfaces (3), and length HAI-I complexed with the serine protease domain of formation of stable complexes (15, 17). We further showed matriptase). M32 MAb only recognizes the 120-kDa complex, but that HAI-I is required for matriptase activation (24), and not the 85-kDa complex (13) . M19 MAb also detects the 55-kDa that both proteins translocate to activation foci during the full-length HAI-1.
activation of the protease (9, 13) . In 184 A1N4 immortal lmmunofluorescence microscopy. Cells were plated onto micro-mammary epithelial cells, while expression levels of cover glasses and grown for 2 days. Cells received different matriptase and HAMI were not uniform among individual treatments, as indicated in each figure. Cells were then fixed and cells, proportional increases or decreases in matriptase and permeabilized in phosphate-buffered saline containing in 0.05% Triton X-100 and 3.7% formaldehyde for 20 rain at room temper-1).
wereloseved compare witi ndividu as (Fg ature, followed by three washes with phosphate-buffered saline. Matriptase, activated matriptase, and HAI-I were detected with HAI-M was even observed when both proteins were transloAlexa Fluor dye-conjugated M32, M69, and M19 monclonal anti-cated to cell-cell junctions during SIP-induced activation of bodies, respectively. F-actin was visualized with Texas red-conju-matriptase (Fig. 1) . Matriptase tended to accumulate more at gated phalloidin (Molecular Probes), and nuclei were stained with the merging points of cell-cell contacts of three or four cells C and F represent merged images.
SIP
(focal points) (Fig. I) . H-IAI-I shared this uneven distribution ever, reduced expression of HAI-I by siRNA in these cells o at cell-cell contacts, with higher levels of matriptase accom-caused spontaneous activation of matriptase ( Fig. 2; M69 , : panied by higher levels of HAL-I (Fig. 1) . Because comparing lane 4 with lane 2). As described previously (13), 0 mnatriptase and HAI-I localization is restricted to common the activated matriptase was detected in 120-and 85-kDa C" points of cell-cell conlact. we sought to further explore the complexes using MAb M69, which specifically recognizes the , 0 role of HAI-I in matriptase activation and intracellular activated, two-chain matriptase. The ratio between 120-and 3 trafficking.
85-kDa complexes varied from experiment to experiment. As Ž.
Reduced expression of HAl-I by HAI-] siRNA caused spon-examined by immunofluorescence
staining, activated 0 taneous activation of matriptase. We reduced the levels of matriptase was detected as a diffuse pattern with some aggre-HAT-1 by HAI-i siRNA to investigate its impact on matriptase gation (Fig. 3) . Because individual cells express different :r activation. After 48 h of treatment with HAI-1 siRNA, 184 amount of HAI-I (Fig. 1) , the reduction of HAI-I expression L. AIN4 expressed much less HAI-1, as examined by immuno-by HAI-siRNA, as seen in immunoblot (Fig. 2) , cannot _ blot using anti-HAl1i MAb M19 ( Fig. 2; M19 , comparing lane clearly be demonstrated by immunofluorescence staining (Fig,   ' < 0 4 with lane 2). The levels of total matriptase were not altered 3). These data suggest that maintenance of a proper ratio a by HAI-i siRNA ( Fig. 2; M32, comparing lane 4 with lane 2) . between matriptase and HAI-I may be essential for prevention 0 As expected from previous studies (1, 2), activation of of spontaneous activation ofmatriptase in mammary epithelial matriptase did not occur in these cells in the absence of an cells. exogenous inducer, such as SIP (Fig. 2, M69, lane 2 
66-
the cell-cell junctions, compared with control cells (Fig. 4) . Because the expression levels of both matriptase and HAI-I 45-varied substantially in individual 184 AIN4 cells, it was difficult to discern the reduced expression of HAI-I-1 by siRNA in some cells. (Fig. 5) . Previously, we showed that elongated manner along cell-cell junctions (Fig. 5B ). Acti-" pretreatment with anti-matriptase MAb M32, which recognizes vated matriptase was detected in almost every single M19-" the third LDL receptor domain of matriptase, inhibited SIP-pretreated cell, but only in approximately one-half of mouse 3 induced matriptase activation in 184 AIN4 cells (9) . Thus we IgG-pretreated cells. Activated matriptase was detected pre-0 incorporated mouse IgG and MAb M32 as controls. After dominately at the junction of multiple cells in the IgG-. being grown for 2 days, the cells were preincubated with 5 pretreated cells, whereas activated matriptase was visual=r Rpg/ml of mouse IgG, M32, or MI9, respectively, for I h. These ized along nearly the entire cell borders of M19-pretreated 0. pretreatments of cells with antibodies alone did not cause cells (Fig. 5B) . 0 matriptase activation, as examined by immunoblot, but acti-HAI-] is required for expression of inatriptase. Given these vated matriptase was observed by immunofluorescence stain-complex and well-coordinated relationships between 0 ing in few scattered M19-pretreated cells (data not shown). matriptase and HAI-1, it seems likely that HAI-I may also 0 After these antibody-pretreated cells were stimulated with SIP play a role during matriptase biosynthesis and degradation. "
for 30 min, activated matriptase was detected in mouse IgG-This notion was first supported when we attempted to C pretreated cells, but not in M32-pretreated ones, as examined exogenously express matriptase in BT549 breast cancer by immunoblot (Fig. 5A) or by immunofluorescence staining cells that do not endogenously express either matriptase or • (Fig. 5B) . Much higher levels of activated matriptase were HAI-1. When BT549 cells were transiently transfected with Fig. 6) . Whereas terminus), with an intervening LDL receptor class A domain Chigh levels of matriptase expression were achieved for the (25) (Fig. 7) . matriptase mutant altered in its active site triad, coexpresThe Kunitz domain is an -60 amino acid long-serine 0 sion of the inactive catalytic triad matriptase mutant with protease inhibitory domain for which the bovine basic 3
wild-type matriptase caused poor expression of both pancreatic trypsin inhibitor represents the prototypic struc-" matriptase species (Fig. 6) . These results suggest that un-ture (4). The P1 residue of Kunitz-type inhibitory domains . opposed matriptase proteolytic activity could be toxic for its (the amino acid residue COOH terminal to the second V
1.
expression, and that the presence of HAI-I corrects this conserved cysteine residue) is recognized as the active U) toxic effect, leading to higher levels of matriptase exprescenter responsible for the inhibitory specificity. For exam-8. sion.
ple, the corresponding amino acid residues in the Kunitz (
Immunofluoresence staining using Texas red conjugated domains of HAI-1 are Arg260 in domain I and Lys385 in 0 phalloidin (actin), together with the anti-matriptase MAb M32 domain II, and therefore these Kunitz domains are predicted o (Fig. 7A) , suggested that the poor expression was due to a to be specific for trypsin-like serine proteases, such as defect in intracellular trafficking of the protease. Indeed, im-matriptase (interacting with Asp799 in the substrate binding C munofluorescence using an antibody that recognizes GM130, a pocket of matriptase). Mutation of Arg260 will completely Gogi-specific marker, together with Alexa Fluor 594-conjuabolish the inhibitory activity of a Kunitz domain. A previgated M32 matriptase-specific antibody (Fig. 7D) , revealed ous study (6) of molecular modeling strongly suggested that that matriptase accumulated in a cellular location consistent the first, but not the second, Kunitz domain of HAI-I is with the endoplasmic reticulum and Golgi apparatus. This responsible for the inhibition of matriptase. In addition to o' defect in trafficking was corrected by cotransfection with Arg260, Arg258 was also suggested to be crucial for the HAI-1, as shown by immunofluorescence (Fig. 7, B and E), and activity of Kunitz domain I. Therefore, we constructed point resulted in much improved expression of the protease, as mutations at these three critical basic residues in Kunitz shown by Western blot analysis (Fig. 7A ). In addition, catalyt-domains I and IL (Arg258, Arg260, and Lys385). ically inactive mutants of matriptase altered in the catalytic Mutation of critical arginine residues in the first Kunitz triad (S805A matriptase) were able to traffic in the absence of domain of HAI-1 (R258L and R260L HIAI-l) completely HAN-1 (Fig. 7C) .
abolished the ability of HAI-1 to facilitate the intracellular The proper trafficking and enhanced expression of the trafficking of matriptase (Fig. 8) . In cotransfection experimatriptase protein when cotransfected with HAI-1 was not a ments with these HAI-1 mutants, matriptase was poorly phenomena limited to BT549 cells. Intdeed, it was also seen expressed, as determined by M32 Western blot analysis, and when matriptase and HAI-i were transfected into MDA MB-did not traffic properly, as determined by matriptase immu-231 and MDA MB-435 cancer cells (data not shown). These nofluorescence (data not shown). However, mutation of a two cancer cell lines also neither express matriptase nor HAI-I critical basic residue in the second Kunitz domain of HAI-1 (22).
(K385L HAI-1) did not affect the ability of HAI-i to The first Kunitz domain, but not the second, is required for facilitate matriptase trafficking because matriptase exHAl-] to facilitate matriptase intracellular trafficking. Because pressed well (Fig. 8) and underwent proper intracellular the intracellular trafficking of matriptase depended on HAI-1, trafficking, as confirmed by matriptase immunofluorescence we were able to test which domains in HAI-I were essential for (data not shown). It should be noted that the R258L and protease expression and trafficking. 
